Novel strategies for Alzheimer's disease treatment: An overview of anti-amyloid beta monoclonal antibodies.
Novel strategies for Alzheimer's disease treatment: An overview of anti-amyloid beta monoclonal antibodies.
复制标题
阿尔茨海默氏病治疗的新型策略：抗淀粉样β单克隆抗体的概述。
DOI：
10.4103/0253-7613.194867
复制
发表时间：
2016-11
影响因子：
2.4
通讯作者：
Rygiel K
中科院分区：
文献类型：
--
作者：
Rygiel K
阿尔茨海默病(AD)是一种多因素的进行性神经退行性疾病，预后不良，因此，在全球范围内，越来越多的老年患者或无症状的个体面临AD的风险，肯定需要新的AD治疗方法。已经证实，一些AD生物标志物，如大脑中的淀粉样β负荷，早于疾病发生约20年。因此，预防或有效治疗AD的治疗必须在症状出现之前开始。这篇综述的一个目的是介绍用于治疗AD的抗淀粉样β蛋白单抗的最新临床试验结果，并解决当前的一些挑战和预防AD的新策略。在最近的试验中，一种单抗，即solanezumab，在轻度AD患者中显示了一些有益的认知效果。正在进行的对Gantenerumab和crenezumab的研究将检查AD治疗的确切时间，目的是改变病程。这项综述基于Medline数据库搜索被动抗AD免疫疗法试验，主要时间范围设定为2012至2015年。
Alzheimer's disease (AD) is a multifactorial, progressive neurodegenerative disorder with a poor prognosis, and thus, novel therapies for AD are certainly needed in a growing population of elderly patients or asymptomatic individuals, who are at risk for AD, worldwide. It has been established that some AD biomarkers such as amyloid-beta load in the brain, precede the onset of the disease, by approximately 20 years. Therefore, the therapy to prevent or effectively treat AD has to be initiated before the emergence of symptoms. A goal of this review is to present the results of recent clinical trials on monoclonal antibodies against amyloid beta, used for the treatment of AD and also to address some of the current challenges and emerging strategies to prevent AD. In recent trials, a monoclonal antibody, i.e. solanezumab has shown some beneficial cognitive effects among mild AD patients. Ongoing studies with gantenerumab and crenezumab will examine when exactly the AD treatment, aimed at modifying the disease course has to be started. This review was based on Medline database search for trials on passive anti-AD immunotherapy, for which the main timeframe was set from 2012 to 2015.
登录
查看更多内容
影响因子：
15.1
作者：
Lemere CA
通讯作者：
Lemere CA
影响因子：
--
作者：
Armstrong RA
通讯作者：
Armstrong RA
DOI：
10.1038/nrneurol.2015.177
发表时间：
2016-01
期刊：
Nature reviews. Neurology
影响因子：
--
作者：
Reiman EM;Langbaum JB;Tariot PN;Lopera F;Bateman RJ;Morris JC;Sperling RA;Aisen PS;Roses AD;Welsh-Bohmer KA;Carrillo MC;Weninger S
通讯作者：
Weninger S
DOI：
10.1097/00005072-199911000-00004
发表时间：
1999-11-01
影响因子：
3.2
作者：
Newell, KL;Hyman, BT;Hedley-Whyte, ET
通讯作者：
Hedley-Whyte, ET
影响因子：
4.8
作者：
Lee, EB;Leng, LZ;Lee, VMY
通讯作者：
Lee, VMY